REMODULIN (TREPROSTINIL) — FDA Approval NDA208276 (UNITED THERAP)
REMODULIN (TREPROSTINIL) — FDA Approval NDA208276 (UNITED THERAP) is one of 9,000 drug approvals in the DrugApprovals dataset. Key details — Brand name: REMODULIN; Active ingredients: TREPROSTINIL; Application number: NDA208276.
| Brand name | REMODULIN |
|---|---|
| Active ingredients | TREPROSTINIL |
| Application number | NDA208276 |
| Sponsor | UNITED THERAP |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS, SUBCUTANEOUS |
| Marketing status | Discontinued |
| Products in application | 4 |
| First approval date | 20180730 |
| Source | openFDA Drugs@FDA |
$1499/mo
Try DrugApprovals →